VALN News - Candlesense

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

(NASDAQ:VALN) Saint-Herblain (France), September 3rd, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme ...

How does VLA15’s efficacy, safety profile, and pricing potential compare to existing or pipeline Lyme disease vaccines from competitors? What is the expected timeline for regulatory approval and commercial launch of VLA15, and how does that align with market demand for a Lyme vaccine? How will the Phase 2 results affect Valneva’s short‑term stock momentum and volatility?

Clinical trials

5 days ago

Read more globenewswire

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

Saint Herblain (France), August 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has...

How might this regulatory action influence Valneva's pipeline timelines and competitive positioning in the arbovirus vaccine market? What is the expected impact of the suspension on VALN's stock price and trading volume? How will the FDA suspension of IXCHIQ® affect Valneva's short-term revenue and cash flow?

Regulation

14 days ago

Read more globenewswire

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for it...

Could the expanded age indication and regulatory clearance lead to broader global roll‑outs or partnership opportunities that impact the stock price? What is the competitive landscape for chikungunya vaccines in Canada and how might this approval influence market share dynamics? How will the Canadian approval of IXCHIQ® affect Valneva's revenue forecasts and valuation?

Regulatory

21 days ago

Read more globenewswire

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Saint-Herblain (France), August 12, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first hal...

How might the half‑year performance influence analyst coverage, earnings estimates revisions, and overall sentiment toward Valneva? Do the results reveal any new risks or upside catalysts that could affect the stock's upside or downside potential? What is the market's expected reaction to the half‑year earnings versus the actual results, and how might that affect short‑term price volatility?

Earnings

27 days ago

Read more globenewswire

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of I...

What are the broader implications for Valneva's overall vaccine franchise and its positioning in the emerging infectious disease market? How might this development influence analyst sentiment and target price revisions for VALN stock? Will the removal of the pause trigger any changes in the company's manufacturing capacity or supply chain requirements?

Regulatory

about 1 month ago

Read more globenewswire